Parasitic Ulcer Treatment Trial

Part of paid clinical trials in San Francisco, California.

Sponsor
Jeremy Keenan, MD, MPH
Study ID
NCT06213649
Phase
PHASE3
Status
Recruiting

Conditions

  • Acanthamoeba Keratitis

Eligibility Criteria

Sex
ALL
Age
8 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Polyhexamethylene biguanide (PHMB) — DRUG
    PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
  • Topical corticosteroid — DRUG
    Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
  • Topical placebo — OTHER
    An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.

Study Details

The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be randomized to one of two treatment groups: * Group 1: Topical corticosteroid * Group 2: Topical placebo

Key Dates

Start date
Jul 1, 2024
Status verified
Apr 2026
Primary completion
Jul 31, 2029
Completion
Jul 31, 2029

Study Design

Enrollment
232 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Topical steroids
    Participants in this arm will receive anti-amoebic therapy plus topical steroids.
  • Placebo Comparator: Topical placebo
    Participants in this arm will receive anti-amoebic therapy plus topical placebo.

Primary Outcome Measure

Vision [ Time Frame: 6 Months ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94158
Krisianne Aromin
Jeremy Keenan, MD, MPH (PRINCIPAL_INVESTIGATOR)
Gerami Seitzman, MD (SUB_INVESTIGATOR)
University of Colorado AnschutzAuroraColorado80045
Travis Redd
7208482020
University of FloridaGainesvilleFlorida32605
Sonal Tuli
University of MiamiMiamiFlorida33136
Guillermo Amescua
University of Illinois, ChicagoChicagoIllinois60612
Elmer Tu
University of IowaIowa CityIowa52242
Mark Greiner
Johns Hopkins UniversityBaltimoreMaryland21287
Nakul Shekhawat
Columbia UniversityNew YorkNew York10032
Leejee Suh
Oregon Health and Science UniversityPortlandOregon97239
Travis Redd
University of PennsylvaniaPhiladelphiaPennsylvania19104
Bennie Jeng
University of Pittsburgh Medical CenterPittsburghPennsylvania15219
Gaurav Prakash, MD
412-647-2200
Baylor College of MedicineHoustonTexas77030
Alejandro Arboleda, MD MS
713-798-5143
University of WashingtonSeattleWashington98104
Minh Nguyen, MD
206-543-7250

Find similar trials in San Francisco, CA